Phillip Capital Research said the company's transfer to the Main Market should provide near-term share price support.
PETALING JAYA: Medical device maker UMediC Group Bhd
(UMC) is expected to post stronger second half financial year 2024 results on the back of expanded manufacturing capacity and better marketing and distribution segments, according to Phillip Capital Research.
“We believe the strong expected earnings, driven by the commencement of the company’s new factory and launch of the care-centre business will serve as the next re-rating catalyst. The transfer to the Main Market, slated for completion by June this year, should provide near-term share price support.
